Top news of the week: 16.05.2022.
Healthcare
First Results From Biotech Co.'s Lymphoma Program Are Impressive Research Report
This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report.
The Ecosystem: Can start-ups thrive in the European Health Data Space?
Proposals to build a European Health Data Space (EHDS) have received a warm welcome from digital health start-ups, which are frustrated by obstacles to scaling-up within Europe.
INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer
Dr. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing ...
HealthTech For Patients 2nd Edition
HealthTech For Patients 2nd EditionTopics that will be discussed during the round tables: Digitalization: New methods to improve patient access to care and develop faster solutions with ...
Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022
Halle (Saale) / Munich, Germany, May 11, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon; or the Company), a clinical stage company focused on discovery ...
Cardiac progenitor cells generate healthy tissue after a heart attack
Following a heart attack, the human body is incapable of repairing lost tissue due to the heart's inability to generate new muscle. However, treatment with heart progenitor cells could ...
New life sciences industry panel to grow Herts key sector and deliver nationwide benefits
A new life sciences industry panel has been convened by Hertfordshire Local Enterprise Partnership (LEP) to drive forward actions that will deliver sustained sector growth, …
Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca’s PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma patients
100% trial success rate across multiple therapy areas continues for Avillion, delivering global pivotal programme of 4 studies with more than 4,000 patients PT027 significantly reduced the ...